Home World News FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a... World News FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 392 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Aromatase inhibitors cut breast cancer recurrence in younger patients February 11, 2022 This Harmful Chemical Is Still Being Used In Popular Household Products June 15, 2021 Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable... February 3, 2022 Liquid Biopsies on the Horizon for Children with Solid Cancers April 11, 2023 Load more HOT NEWS Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 EMA Recommends Granting a Marketing Authorisation for Camizestrant Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief... ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ
